Aimisen

Wuhan Aimisen Life Technology Co., Ltd. was established in January 2015. It is a high-tech enterprise focusing on the research and development, registration, production, and sales of early non-invasive detection products for high-incidence malignant tumors worldwide, and is committed to the global promotion of early cancer diagnosis technology products. Aimisen is a high-tech enterprise, a specialized and sophisticated "Little Giant" enterprise, the fourth batch of specialized and sophisticated "Little Giant" enterprises in Hubei Province, a hidden champion in a segmented field in Hubei Province, a gold seed enterprise for listing in East Lake High-tech Development Zone, a silver seed enterprise for listing in Wuhan City, and has been selected as a gazelle enterprise in East Lake High-tech Development Zone for five consecutive years, among others. Its products and technologies have been recognized as internationally advanced by the Ministry of Industry and Information Technology and the Hubei Provincial Department of Science and Technology, and won the first prize of the "Invention and Entrepreneurship Award Achievement Award" of the China Association of Inventions. Aimisen has established a comprehensive cancer early screening technology platform. Its product line is the most complete in the industry, it is the enterprise with the most certificates in the industry and the most intellectual property rights in the industry. For high-incidence single-cancer or multi-cancer combined testing, it has developed 21 products and more than 20 supporting kits, including 11 products for single cancer and 10 products for pan-cancer detection. Aimisen's products are all independently developed, with more than 150 patent applications in China, 55 authorized patents, and nearly 10 overseas patents. Aimisen has established a strong expert team in multiple fields and heavyweight strategic partners in the industry. Multiple projects are led by academicians and participated in by industry committee chairmen. It has also reached strategic partnerships with internationally renowned pharmaceutical companies such as Roche Diagnostics and Eurofins, and its overseas customers are distributed in more than 30 countries. It strives to truly achieve early, non-invasive, and precise tumor detection, and fundamentally reduce the incidence and mortality of tumors.